Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

The company was founded in 2023 and is based in Saint-Laurent, Canada.

enGene Holdings Inc.

Country	Canada
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	33
CEO	Ronald H. Cooper

Contact Details

Address: 7171 Rue Frederick Banting Saint-Laurent, QC H4S 1Z9 Canada
Phone	514 332 4888
Website	engene.com

Stock Details

Ticker Symbol	ENGN
Exchange	NASDAQ
Fiscal Year	November - October
Reporting Currency	USD
CIK Code	0001980845
CUSIP Number	46429B226
ISIN Number	CA29286M1059
SIC Code	2836

Key Executives

Name	Position
Dr. Alex Nichols Ph.D.	President and Chief Operating Officer
Lee G. Giguere	Chief Legal Officer and Corporate Secretary
Sharon Tan	Vice President of Project Management and Head of Program Management
Dr. Raj Pruthi M.D.	Chief Medical Officer
Paul Erickson	Non-Executive Director

Latest SEC Filings

Date	Type	Title
Nov 1, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Oct 28, 2024	424B3	Prospectus
Oct 25, 2024	8-K	Current Report
Oct 21, 2024	SCHEDULE 13G/A	Filing
Oct 21, 2024	424B3	Prospectus
Oct 21, 2024	8-K	Current Report
Oct 18, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Sep 26, 2024	424B3	Prospectus
Sep 26, 2024	8-K	Current Report
Sep 10, 2024	424B3	Prospectus

View All SEC Filings